ABT · News · 20261107N
Product Launch and Transition
ABBOTT LABORATORIES · 2026-11-07 · Importance 58 · Surprise 42 · In source text
Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder in late October or early November 2026. The company reported strong study results for the investigational Amulet 360 and SonicForce coronary intravascular lithotripsy system. Abbott also commercially launched the next-generation Oncodetect minimal residual disease test, expanding its offerings in cardiology procedures and cancer monitoring.
Key facts
- Abbott commercially launched the next-generation Oncodetect MRD test. source
- In late October and early November 2026, Abbott reported strong study results for the investigational Amulet 360. source
- In late October and early November 2026, Abbott reported strong study results for the investigational SonicForce coronary IVL system. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Abbott commercially launched the next-generation Oncodetect MRD test. |